Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients

BioSpace

With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics.

Policy / PricingNeuroscienceRead full story